Search

Search
- Search

REDEFINING ADC PRECISION: NATURE’S BLUEPRINT, OUR BREAKTHROUGH

Scientific Platforms

Manhattan BioSolutions engineers next-generation antibody-drug conjugates (ADCs) inspired by evolutionary mechanisms, delivering unparalleled tumor targeting and payload release to conquer advanced cancers. The ADCs are designed to selectively eliminate cancer cells via multiple immune-mediated or direct anti-tumor mechanisms

>>>

In the News

Manhattan BioSolutions Secures Expanded Rights to Novel Legumain-Cleavable Topoisomerase 1 Inhibitor (TOP1i) ADC Platform After Successful Multi-Target Validation

Manhattan BioSolutions Initiates NCI PIVOT Collaboration in Pediatric Cancers

Manhattan BioSolutions Partners to Advance Taxoids as Innovative ADC Payloads

Manhattan BioSolutions, Inc. Announces Collaborative Poster Presentation on Novel FGFR4-Targeted ADC at AACR Annual Meeting 2024

Nascent Biotech and Manhattan BioSolutions Collaborate to Explore Pritumumab Antibody-Drug Conjugates

Manhattan BioSolutions Named as an Awardee of Science in the City QuickFire Challenge

Manhattan BioSolutions Enters Into Collaboration Agreements with the NIH and Binghamton University to Develop Novel ADC

Manhattan BioSolutions, Inc. Selected to be Featured in New York Pavilion at BIO International Convention

Manhattan BioSolutions, Inc. Enters into License Option Agreement with Wisconsin Alumni Research Foundation (WARF) for the RNA Nuclease Technology

Manhattan BioSolutions, Inc. Signs Commercial Evaluation License Agreements with the National Institutes of Health (NIH) for Use of Monoclonal Antibodies in Novel Antibody-Drug Conjugate (ADC) Oncology Programs

Manhattan BioSolutions Enters into a Research Collaboration And License Option Agreement with Binghamton University for the New Linker-Payload Technology

Grant Award from the University at Buffalo Center for Advanced Technology in Big Data and Health Sciences

Manhattan BioSolutions Announces Grant Award from the New Jersey CSIT

EVQLV and Manhattan BioSolutions Announce Grant Award from UB CAT

Manhattan BioSolutions Announces Positive Preclinical Data Validating its Novel Synthetic Microbial Therapeutic Platform

Manhattan BioSolutions to Present at the ACCESS CHINA Forum @JPM WEEK 2021

Manhattan BioSolutions Announces Phase I SBIR Grant Award from the National Science Foundation

EVQLV and Manhattan BioSolutions Enter into Strategic Collaboration to Discover Novel Antibody-Based Therapies

Manhattan BioSolutions Signs an Option to Exclusive License Agreement with the University at Buffalo to Develop Novel Monoclonal Antibody Targeting a Multiligand Receptor Involved in Inflammatory Responses and Cancer

Nascent Biotech and Manhattan BioSolutions Enter into Collaboration to Advance Vaccine Discovery and Development for COVID-19

Manhattan BioSolutions establishes new laboratory space at the JLabs JNJ Innovation incubator in New York City

Manhattan BioSolutions has been awarded Phase 1 SBIR Grant from the National Cancer Institute, National Institute Of Health

Manhattan BioSolutions has won prestigious Johnson & Johnson Innovation QuickFire Challenge Competition and award to receive free laboratory and office space at the newly open JLabs@NYC incubator in downtown Manhattan

Manhattan BioSolutions has been awarded REACH grant from the New York State Center For Biotechnology at the Stony Brook University

Manhattan BioSolutions secures non-dilutive angel funding

Contact Us

For business development or general inquiries, please fill out a contact form. If you’re an accredited investor, please contact us at borys . shor at manhattanbiosolutions . com or connect on LinkedIn

HQ
JLabs JNJ 101 6th Avenue, 3rd Floor
New York, NY 10013

Laboratory
80 5th Avenue, 1007
New York, NY 10011